Channel Pharma (PTHS) - מזומנים למניה אחת

Channel Therapeutics - לוגו גרפי של המנפיק PTHS

Channel Therapeutics (PTHS) reduces regulatory threats through a diversified molecule portfolio, while the development of therapies for rare CNS pathologies drives acquisition potential. Cash per share currently prices in the balance of these factors, where the 4.65 metric determines this level. Stability is maintained via digital oversight of external trials and the creation of substance reserves to minimize reliance on contractors.

Channel Therapeutics Corp (PTHS) - מזומנים למניה מ-03.07.2025 עד 20.11.2026

פילוחים אנליטיים של חברת Channel Therapeutics

- מחיר שוק ויעדי מחיר של אנליסטים:
- מדדי זמינות כספים ותזרימי מזומנים:
ניתוח מסכם של החברה:PTHS (Channel Pharma)
דוגמת מוצר של Channel Therapeutics Inc.

This metric reflects the actual liquidity of the business divided by the number of shares, which allows for the elimination of accounting distortions and the impact of secondary offerings. For Channel Therapeutics (PTHS), a stable working fund is ensured by the protected status of medical research within the US legal framework. The cash per share trend confirms the effectiveness of reserve management amid minimal geopolitical risks. This chart reveals the true state of the company's balance sheet. Growth in this metric indicates fundamental stability and the financial security of the business.